Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

Please provide your email address to receive an email when new articles are posted on . CV benefits of PCSK9 inhibition with evolocumab may be stronger in patients with autoimmune or inflammatory ...

The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

PARIS, France—Eight weeks of evolocumab (Repatha; Amgen) added to a regimen of high-intensity statins following an ACS event was safe and vastly reduced LDL cholesterol levels compared with statins ...

The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age ...

Research on competing PCSK9 inhibitors was shared at the European Society of Cardiology 2019 Congress in Paris, France. New results for Sanofi-Regeneron’s alirocumab, sold as Praluent, and Amgen’s ...

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major cardiovascular event among adults with atherosclerotic cardiovascular disease ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

The PCSK9 inhibitor evolocumab (Repatha, Amgen) is far too expensive to make economic sense for the healthcare system and private payers, according to the results of yet another cost-effectiveness ...

We checked this guidance and found nothing new that affects the recommendations. For more information, see the review decision. Next review: This guidance will be reviewed if there is new evidence ...

The appraisal committee considered evidence from a number of sources. See the committee papers for full details of the evidence. The company did a systematic literature review, and identified 4 ...